Clinical lymphoma, myeloma & leukemia
Real-World Outcomes of High Dose Melphalan and Autologous Stem Cell Transplantation in Patients With Multiple Myeloma Older and Younger Than 65 Years.
Koen M Klomberg, Miriam Gelderloos, Hilde A M Kooistra, Marcel Nijland, Geertruida H de Bock, Gerwin A Huls, Mirian Brink, Wilfried W H Roeloffzen, Wouter J Plattel
Published: 202510.1016/j.clml.2025.12.007
Abstract
BACKGROUND: High dose chemotherapy followed by autologous stem cell transplantation (HDT/ASCT) remains the preferred consolidation strategy for patients with newly diagnosed multiple myeloma (MM). While its use has expanded to patients over 65 years…
Preview only. Read the full abstract at the source